Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm (SCORPION)
This study is currently recruiting participants.
Verified October 2011 by Catholic University of the Sacred Heart
Catholic University of the Sacred Heart
Information provided by (Responsible Party):
Prof. Giovanni Scambia, Catholic University of the Sacred Heart
First received: October 19, 2011
Last updated: October 26, 2011
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||September 2013|
|Estimated Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53.
Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, Salerno MG, Scambia G. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008 Dec;199(6):642.e1-6. Epub 2008 Sep 17.